Arrhythmia induced cardiomyopathies (AIC) refer to the collective condition of Arrhythmia, Tachycardia, and ectopy-induced Cardiomyopathy. Atrial fibrillation (AF) and heart failure (HF) are modern epidemics that often coexist and exacerbate one another. We aim to provide an overview of the current understanding and evidence for treatment and management in AIC with a particular focus on AF-mediated cardiomyopathy and suggest approaches to recognize, screen, and manage AIC.
| INTRODUCTION
Arrhythmias represent an important reversible cause for left ventricular systolic dysfunction. [1] [2] [3] [4] [5] [6] [7] [8] However, arrhythmias may be under recognized leading to a delay in intervention. 9 With the advent of catheter ablation, an effective tool is available which can restore sinus rhythm without the detrimental effects of drug toxicity. 9, 10 For the purpose of this review, we will use the term Arrhythmia-induced cardiomyopathies (AIC) to refer to the collective condition of Tachycardia and ectopy-induced Cardiomyopathy.
Atrial fibrillation (AF) and heart failure (HF) are modern epidemics that often coexist and exacerbate one another. 11 CAMERA-MRI 7 and CASTLE-AF 2 are two pivotal studies which highlight the role of atrial fibrillation in systolic heart failure. We aim to provide an overview of the current understanding and evidence for treatment and management in AIC with a particular focus on AF-mediated cardiomyopathy and suggest approaches to recognize, screen, and manage AIC.
| WH AT IS AIC?
Arrhythmia induced cardiomyopathies was first described in 1913
but it was not until 1962 that the reversible nature of the condition was appreciated. 12, 13 AIC is defined by sufficient supraventricular or ventricular arrhythmia to result in Left ventricular (LV) systolic dysfunction. 9 The arrhythmia can either be sustained, paroxysmal, or highly frequent ectopic activity. 9, 14, 15 The arrhythmia duration which preceded the development of LV dysfunction is often difficult to determine as symptom onset is often insidious with progressive fatigue and dyspnea without palpitations. In animal models, AIC can be reproduced with rapid pacing for 1-2 months. 16 Once the arrhythmia is corrected recovery of LV function is seen within 6 weeks. 10 Most patients with AIC can expect to improve their LV function to normal levels with an overall favorable prognosis. Nonetheless there is a small risk of sudden cardiac death particularly in the setting of arrhythmia recurrence or where the cardiomyopathy is of mixed etiology including coronary disease. 10, 17 AIC can occur with a wide range of arrhythmia (Table 1 ). The prevalence of AIC is estimated at 8%-28% with focal atrial tachycardia (FAT) and 10%-34% of patients with premature ventricular complex (PVC) and nonsustained ventricular tachycardia (VT). 18 Only until recently has the definition of AIC started to include arrhythmias other than tachycardia. 8 Arrhythmia induced cardiomyopathies has a wide range of clinical presentations and may be entirely responsible for the cardiomyopathy (Type 1) or be contributory to an underlying CM with an alternate etiology (Type 2). 19 Hence, two categories of AIC have been proposed. 9, 20 • Type 1 AIC: Arrhythmia induced. This is when arrhythmia is solely responsible for AIC and the LV function returns to normal upon successful treatment of the arrhythmia.
• Type 2 AIC: Arrhythmia mediated. Arrhythmia exacerbates the underlying cardiomyopathy and treatment of the arrhythmia results in partial resolution of the cardiomyopathy. In humans, AIC is more unpredictable with a second factor, likely a genetic susceptibility, to explain why a similar burden of arrhythmia can have such variable effects on systolic function in different individuals. 10 Tachycardia at >100 bpm 4 and >15% of the day has the potential to result in AIC. 20 Timing of onset of arrhythmia to clinical presentation or LV deterioration can vary widely and depend on duration of sustained arrhythmia, coexisting structural heart disease, and patients' age. 
| AF-MED IATED CARDIOMYOPATHY
Atrial fibrillation is the most common cause of AIC in adults 9, 10, 32 and the association between AF and AIC has been well described.
AF and HF are modern epidemics which often coexist and precipitate one another. 11 In the Framingham study, those with AF had a higher risk of developing HF (HR of 2.22 [CI 1.47-3.34]
The pathophysiologic mechanisms underlying development or progression of cardiomyopathy in patients with AF include: tachycardia, heart rate irregularity, loss of atrial systolic function, and genetic factors.
Irregular contraction leads to adverse hemodynamic consequences that are independent of heart rate. 33, 34 The contribution of irregularity is demonstrated in patients with rate controlled AF and LV dysfunction, who improve LV function following atrioventricular nodal ablation which regularizes ventricular rhythm with pacing. 33, 35 Furthermore, atrioventricular dyssynchrony can impair diastolic filling which in turn worsens diastolic function thereby leading to increased left sided pressure and negative atrial remodeling which in turn perpetuates AF. 36, 37 Coordinated atrial contraction contributes up to 20% of cardiac output and loss of atrial contraction adversely affects cardiac output in AF. 8, 33, 38 It is likely that AF unmasks an underlying tendency and susceptibility to develop cardiomyopathy in patients with AIC. 37 A wide range of genetic mutations such as encoding molecules involved in In the CAMERA-MRI trial, 7 68 patients with persistent AF and idiopathic cardiomyopathy (EF < 45%) were randomized (1:1) to optimal rate control or catheter ablation to restore sinus rhythm and fol- group. Subgroup analysis demonstrated greater benefit in LVEF of 25%-35% vs <25%. Both lower mortality and heart failure admission contributed to the primary endpoint, but heart failure effects were apparent much earlier at 6 months compared to a mortality benefit which became significant at 3 years. The cornerstone of the ablation strategy was pulmonary vein isolation (PVI) with additional ablation at the discretion of the operator. The AF burden in the ablation group was 20%-27% compared with 48%-64% in the medical group.
These 2 significant trials demonstrate the importance of restoration of sinus rhythm with catheter ablation in patients with AF and systolic heart failure with improvements in LVEF, quality of life, heart failure hospitalization and total mortality.
| PVC CARDIOMYOPATHY
The incidence of AIC in patients with PVC's has been estimated between 9% and 34%. 18, 31 The mechanism responsible for PVCinduced cardiomyopathy is likely explained by 8 ventricular dyssynchrony and abnormal ventricular contraction. 49 The mechanism is akin to that seen in RV pacing-induced cardiomyopathy with redistribution of myocardial strain and work, 50 decreased adrenergic Importantly, AIC was not seen with a PVC burden of less than 10%
and was predominantly confined to those with a PVC burden of >20%. 54 Penela et al suggested a PVC burden of ≥13% as the ideal cut off to predict LV recovery with a sensitivity of 100% and a specificity of 85% independent of coexistent structural heart disease. 55 In a retrospective study, catheter ablation was superior to antiarrhythmic therapy with beta blockers, calcium channel blockers, or amiodarone with a 93% reduction in PVCs 56 The benefit of PVC ablation was observed even in those with underlying structural heart disease with a EF improvement of 10%-15%. 57 Factors that may increase risk of AIC include: wider the QRS (>150 ms), 14, 58 presence of nonsustained VT, multifocal PVC and RV PVC's. 59 Hence, any patient with LV dysfunction and a PVC burden of >20% should be considered for ablation or pharmacologic strategies to reduce arrhythmia burden. 60 
| MANAGEMENT OF AIC
Management algorithm for suspected AIC is presented in Figure 4 .
Although there are no specific recommendations in the guidelines defining the role of catheter ablation in patients with AF and HF, the evidence in favor of catheter ablation is mounting. 
| CONCLUSION
Arrhythmias are an under recognized cause of LV systolic dysfunction.
Atrial fibrillation is the commonest form of arrhythmia responsible for cardiomyopathy with rate control alone inferior to restoration of sinus rhythm with catheter ablation. Catheter ablation in patients with AF and systolic dysfunction results in improvements in heart failure symptoms, LVEF with reductions in hospitalizations and total mortality, and should be considered first line in this patient population. 
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